EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Breast Cancer: Molecular Pathogenesis and Targeted Therapy

Md Abdus Samad, Iftikhar Ahmad, Mohammad Rashid Khan, Mohd Suhail, Torki A Zughaibi, Fahad A Al-Abbasi, Khaled A Alhosaini, Mohd Shahnawaz Khan, Ajoy Kumer, Shams Tabrez iD

MedComm · 2025-10 · 6 (10)

DOI: 10.1002/mco2.70404 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 04.10.2025. Verfasst von Md Abdus Samad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry Faculty of Science King Abdulaziz University Jeddah Saudi Arabia. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 725 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the most prevalent cancer in women and remains the leading cause of cancer‐related mortality globally. Its development is influenced by multiple factors, including genetics, environmental, aging, and modulation of various signaling pathways. The heterogeneity of BC together with the emergence of treatment resistance and recurrence have prompted researchers to explore and develop new therapeutic approaches. Recently, oncology research has primarily focused on the development of targeted therapies against molecular abnormalities in BC. These therapies include monoclonal antibodies, tyrosine kinase inhibitors, antibody–drug conjugates, PI3K/Akt/mTOR pathway inhibitors, CDK 4/6 inhibitors, PARP inhibitors, antiangiogenic agents, and various other targeted drugs. Immunomodulatory strategies, including immune checkpoint inhibitors (anti‐PD‐1/PD‐L1), CTLA‐4 blockers, adoptive T‐cell therapy, and cancer vaccines, stimulate immune response against cancer cells. Epigenetic therapies like DNMT and HDAC inhibitors have also shown promise in BC treatment. This review highlights how innovative approaches like targeting intratumoral heterogeneity, liquid biopsy for resistance mutation detection, bypass mechanisms ( FGFR1 activation following CDK4/6 inhibition), artificial intelligence‐based drug discovery, patient‐derived organoids, and adaptive trial designs are shaping BC treatment. By combining molecular insights with precision therapeutics, these advancements offer significant potential to address resistance, improve efficacy, and enhance patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

PARP inhibitorsPI3K/Akt/mTOR inhibitorsartificial intelligencebreast cancer subtypestargeted therapytumor microenvironment

Autor:innen und Institutionen

  • Department of Biochemistry Faculty of Science King Abdulaziz University Jeddah Saudi Arabia.
  • King Fahd Medical Research Center King Abdulaziz University Jeddah Saudi Arabia.
  • Department of Pharmacology and Toxicology College of Pharmacy King Saud University Riyadh Saudi Arabia.
  • Department of Medical Laboratory Sciences Faculty of Applied Medical Sciences King Abdulaziz University Jeddah Saudi Arabia.
  • Protein Research Chair Department of Biochemistry College of Sciences King Saud University Riyadh Saudi Arabia.
  • Department of Chemistry College of Arts and Sciences International University of Business Agriculture & Technology (IUBAT) Dhaka Bangladesh.

ORCID-Profile: Shams Tabrez

Zitieren

APA

Samad, M. A., Ahmad, I., Khan, M. R., Suhail, M., Zughaibi, T. A., Al-Abbasi, F. A., Alhosaini, K. A., Khan, M. S., Kumer, A., & Tabrez, S. (2025). Breast Cancer: Molecular Pathogenesis and Targeted Therapy. MedComm, 6(10). https://doi.org/10.1002/mco2.70404

Vancouver

Samad MA, Ahmad I, Khan MR, Suhail M, Zughaibi TA, Al-Abbasi FA, et al. Breast Cancer: Molecular Pathogenesis and Targeted Therapy. MedComm. 2025;6(10). doi:10.1002/mco2.70404

BibTeX
@article{Samad2025,
  author = {Samad, Md Abdus and Ahmad, Iftikhar and Khan, Mohammad Rashid and Suhail, Mohd and Zughaibi, Torki A and Al-Abbasi, Fahad A and Alhosaini, Khaled A and Khan, Mohd Shahnawaz and Kumer, Ajoy and Tabrez, Shams},
  title = {Breast Cancer: Molecular Pathogenesis and Targeted Therapy},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {10},
  doi = {10.1002/mco2.70404}
}
Kostenlos starten →